Tag: bipolar disorder

Letter to the Editor: Bipolar I Disorder Exacerbation and COVID-19 Vaccination: Correspondence
Funding/financial disclosures. The authors have no conflict of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2023;20(1–3):8. Dear Editor: We would like to discuss the article, “Bipolar I Disorder Exacerbation Following COVID-19 Vaccination,”1 wherein Guina et al1 described the cases of a […]

Role of TNF-α -308G/A Polymorphism in Bipolar Disorder and its Relationship with Clinical and Demographic Variables
by Shama Akram, MPhil; Moazzam Ali, PhD; Zeeshan Mutahir, PhD; Nabeel Ibad, FCPS; Sana Sarmad, MPhil; Sumaira Mehboob, PhD; and Mahjabeen Saleem, PhD Ms. Akram and Drs. Ali and Mutahir are with School of Biochemistry and Biotechnology, University of the Punjab in Lahore, Pakistan. Dr. Ibad is with Shaikh Zayed Hospital in Lahore, Pakistan. Dr. Sarmad is […]

Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments
by Philip D. Harvey, PhD; Michelle L. Miller, MS; Raeanne C. Moore, PhD; Colin A. Depp, PhD; Emma M. Parrish, BS; and Amy E. Pinkham, PhD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and Research Service at Bruce W. Carter VA Medical Center in Miami, Florida. Ms. […]

The Role of Serum Lithium Concentration on Pill Burden in Psychiatric Populations
by Charisse Chehovich, PharmD; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Emily Leppien, PharmD, BCPS; and Eileen Trigoboff, RN, PMHCNS-BC, DNS, DABFN Drs. Chehovich, Demler, and Trigoboff are affiliated with the Buffalo Psychiatric Center, New York State Office of Mental Health in Buffalo, New York and with the University at Buffalo School of Pharmacy […]

An Open-Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder
by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Driscoll is with the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Smith is with the […]

MicroRNAs as Biomarkers for Psychiatric Conditions: A Review of Current Research
by Anoop Narahari, MD; Mariyah Hussain, MD; and Venkatesh Sreeram, MD Drs. Narahari, Hussain, and Sreeram are from the University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama. Innov Clin Neurosci. 2017;14(1–2):53–55. Funding: No funding was received for the preparation of this article. Financial disclosures: The authors have no conflicts of interest relevant to […]

Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie Citrome, MD, MPH Dr. MacEwan and Ms. van Eijndhoven are with Precision Health Economics in Los Angeles, California, USA; Dr. Seabury is with the University […]

Letter to the Editor: Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label medications in psychiatric settings.[1] Despite limited evidence, it has been used frequently in the treatment of mood and anxiety disorders in patients with comorbid substance […]

The Neuroscience Report—Vol. 33 (January 11, 2016): Bipolar Disorder
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This week’s topic: Bipolar […]

Letter to the Editor: Comparing Injection Site Pain with Paliperidone Palmitate Versus First-generation Depot Antipsychotics in Subjects with Schizophrenia
Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from 10 different studies reported a 30-percent decrease in the relative risk for relapse with LAIs versus oral antipsychotic medications.[2] However, first-generation depot medications, such as […]